NASDAQ:OCS • CH1242303498
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for OCULIS HOLDING AG (OCS).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-05 | Stifel | Maintains | Buy -> Buy |
| 2026-03-04 | Needham | Maintains | Buy -> Buy |
| 2026-03-04 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-19 | Stifel | Maintains | Buy -> Buy |
| 2025-12-19 | JP Morgan | Initiate | Overweight |
| 2025-12-03 | LifeSci Capital | Initiate | Outperform |
| 2025-11-13 | B of A Securities | Maintains | Buy -> Buy |
| 2025-11-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-11 | Needham | Reiterate | Buy -> Buy |
| 2025-11-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-10-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-27 | Needham | Initiate | Buy |
| 2025-08-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-17 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-13 | Baird | Maintains | Outperform -> Outperform |
| 2025-03-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-01-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A 479.73% | N/A 215.13% | N/A 39.28% | N/A 190.35% | N/A 43.43% | N/A 54.49% | N/A 31.59% | |||||||
| EBITDA YoY % growth | -12.11M | -12.99M -7.27% | -32.08M -146.96% | -45.564M -42.03% | -72.798M -59.77% | -81.126M -11.44% | N/A -24.96% | N/A -13.81% | N/A -2.09% | N/A 60.85% | N/A 723.58% | N/A 134.00% | N/A 88.16% | N/A 43.52% | |
| EBIT YoY % growth | -12.34M | -13.23M -7.21% | -32.38M -144.75% | -45.851M -41.60% | -73.204M -59.66% | -81.672M -11.57% | N/A -22.12% | N/A -23.25% | N/A 40.71% | N/A -57.39% | N/A 215.77% | N/A 186.04% | N/A 88.28% | N/A 42.20% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -1.53 | -2.10 -37.25% | -1.92 8.57% | N/A 5.97% | N/A -8.11% | N/A 35.29% | N/A -15.06% | N/A 225.03% | N/A 46.09% | N/A 92.10% | N/A 35.26% |
All data in CHF
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.42 38.66% | -0.46 6.66% | -0.48 -49.96% | -0.44 -5.42% |
| Revenue Q2Q % growth | 213.14K -25.21% | 213.14K -18.34% | 213.14K -12.29% | 5.973M 1,353.28% |
| EBITDA Q2Q % growth | -23.136M -16.55% | -25.749M -25.41% | -27.206M -36.66% | -29.444M -46.58% |
| EBIT Q2Q % growth | -24.098M -20.65% | -26.503M -27.61% | -28.435M -40.10% | -24.447M -18.49% |
All data in CHF
15 analysts have analysed OCS and the average price target is 48.14 USD. This implies a price increase of 77.39% is expected in the next year compared to the current price of 27.14.
OCULIS HOLDING AG (OCS) will report earnings on 2026-05-07, before the market open.
The consensus EPS estimate for the next earnings of OCULIS HOLDING AG (OCS) is -0.42 USD and the consensus revenue estimate is 213.14K USD.
The expected long term growth rate for OCULIS HOLDING AG (OCS) is 440.39%.